STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #570 by analyst upside · 2026-08-13
RCKT
Rocket Pharmaceuticals, Inc.
Healthcare · Market Cap $374M · P/E 0x
ANALYST PRICE TARGET
+159.3%
implied upside to consensus target
Current Price $3.41
Consensus Target $8.84
Bull Target $15.0
Bear Target $3.0
Analysts Covering 11
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
5
Hold
5
Sell
1
52-Week Low $2.53
52-Week High $5.45
YTD Return -1.4%
FUNDAMENTALS
Market Cap $374M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.17
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.53
52-Week High $5.45
Current Price $3.41
Bear Target $3.0
Bull Target $15.0
● Now $3.41 ● Target $8.84
TRADING DATA
Avg Volume 2.4M
YTD Return -1.4%
Analyst Count 11
Consensus Hold
Upside to Target +159.3%
Last Updated 2026-08-13

ANALYST SUMMARY

Rocket Pharmaceuticals, Inc. (RCKT) is currently trading at $3.41 with a Wall Street consensus price target of $8.84, implying potential upside of 159.3% over the next 12 months. 11 analysts currently cover RCKT, with a consensus rating of Hold - 45% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.0, while the most cautious has a target of $3.0.

RCKT operates in the Healthcare sector with a market capitalisation of $374M. The stock is down 1.4% year-to-date and is currently trading near the lower end of its 52-week range of $2.53 – $5.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RCKT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital - Reiterated
Buy → Buy 2026-05-11 33% win rate (6 calls)
B of A Securities - Reiterated
Buy → Buy 2026-03-30 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-03-27 33% win rate (6 calls)
Goldman Sachs - Reiterated
Sell → Sell 2026-03-02 Building track record
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-02-27 40% win rate (10 calls)
B of A Securities - Reiterated
Buy → Buy 2025-11-18 Building track record
JP Morgan ↓ Downgrade
Overweight → Underweight 2025-11-18 43% win rate (7 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-10-14 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
26
out of 100
Coverage depth
19/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →